SYDNEY, Aug. 27, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) is pleased to announce that Dr Malcolm McColl, Chief Executive Officer will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference, Millennium Broadway Hotel, New York.
The presentation, on Tuesday September 10, 2013 at 2pm, Eastern US time, will provide a company overview with a focus on the strong interim results from the Phase 2 clinical trial of Viralytics' lead product CAVATAK for the treatment of late-stage melanoma.
Dr McColl will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.
Intratumourally administered CAVATAK is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US. Viralytics also plans to commence a Phase 1/2 study of CAVATAK delivered intravenously in patients with melanoma, prostate, lung or metastatic bladder cancers prior to the end of 2013 (the STORM study).
Based in Sydney Australia, Viralytics is listed on the Australian Securities Exchange (ASX: VLA) while its ADRs also trade under VRACY on the US OTCQX International market. For more information on the company, please visit http://www.viralytics.com.
For Viralytics Ltd:
US Investor Contacts:
Dr. Malcolm McColl
+612 9988 4000
Joshua Drumm, Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.